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Aims and method To systematically review the literature on barriers to the use
of clozapine and identify any interventions for optimizing clozapine use in
treatment-resistant schizophrenia. Journal databases were searched from 1972 to
March 2018. The following search terms were used: treatment-resistant
schizophrenia, clozapine, barriers, use, prescription rates, implementation, clozaril
and prescribing practices. Following a review of the literature, 15 papers were
included in the review.
Results The major barriers that were identiﬁed included mandatory blood testing,
fear of serious side-eﬀects and lack of adherence by the patients, diﬃculty in
identifying suitable patients, service fragmentation, and inadequate training in or
exposure to using clozapine.
Clinical implications In view of consistent evidence across the studies on
inadequate knowledge and skills as a signiﬁcant barrier, we suggest that a
certiﬁcation requiring competence in initiating and managing side-eﬀects of
clozapine becomes a mandatory requirement in training programmes.
Declarations of interest None.
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Clozapine use in schizophrenia
Clozapine is the only medication licensed for treatment-
resistant schizophrenia (TRS), which aﬀects about one-third
of those suﬀering from the disorder. Recently, there has
been increased interest in redeﬁning the role of clozapine
in the treatment of schizophrenia in view of the evidence
of superior eﬃcacy and safety, despite serious side-eﬀects.1
Meta-analyses have demonstrated that clozapine is signiﬁ-
cantly better at treating symptoms than ﬁrst-generation
antipsychotics and some (but not all) second-generation
antipsychotics.2 This superior eﬃcacy was also supported
by two large, independently funded studies.3,4 Clozapine
also appears to have broader eﬀects, with evidence for eﬃ-
cacy in suicidality, aggression and substance misuse.1 In
the USA, clozapine is approved by the Food and Drug
Administration for the management of suicidality in
people with schizophrenia or schizoaﬀective disorder. In
addition, clozapine has been shown to have anti-aggressive
properties5 and may also be eﬀective in diminishing sub-
stance misuse.6,7 Tiihonen et al7 found, using a large data-
base, that that people regularly taking clozapine had the
lowest risk of premature mortality compared with both
those on other antipsychotics and those not taking regular
medication, despite the fact that the drug is associated
with a number of serious adverse side-eﬀects.7
Potential barriers and delays in clozapine use
Despite the evidence of superior eﬃcacy and recommenda-
tions by diﬀerent treatment guidelines, the drug is grossly
underutilised.8 Studies based on prescription patterns in
routine practice almost universally show lower prescriptions
of clozapine in individuals with Schizophrenia, even after
taking into account potential barriers such as inadequate
service provision.9 There is also substantial evidence that
the use of clozapine is delayed for several years, which
may result in less than optimal eﬃcacy for the drug.
A study by Howes et al10 showed that the mean theoretical
delay from meeting the National Institute for Health and
Care Excellence (NICE) criteria for TRS and starting cloza-
pine was about 4 years. In New Zealand the theoretical delay
was almost 10 years.11 In the USA, only six states reported
that more than 10% of Medicaid-eligible patients with
schizophrenia had received a prescription of clozapine.12
The reasons for such suboptimal use of clozapine
remain obscure, and may include several factors related to
patients, carers and clinicians. These may include the per-
ception of the drug as a dangerous medicine1 or diﬃculties
associated with initiating and maintaining the treatment.
The life-threatening side-eﬀects of clozapine and mandatory
requirement for white blood cell (WBC) counts may partly
account for the less than optimal use of the drug in clinical
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practice. Experience in using clozapine may be an important
factor. A study by Nielsen et al13 of the attitudes and knowl-
edge of 137 psychiatrists in Denmark, including 100 consult-
ant psychiatrists, revealed that some had never prescribed
clozapine despite having worked for over 5 years. The bar-
riers to eﬀective use of clozapine have not been reviewed
systematically.
We therefore aimed to review the literature on barriers
to the eﬀective use of clozapine in clinical practice for TRS.
We also wanted to identify any interventions that could
potentially improve the use of clozapine. This systematic
review aimed to answer the following questions.
• What barriers or factors have been identiﬁed that prevent
the optimal use of clozapine in TRS, based on the current
literature?
• What strategies have been explored to promote the eﬀect-
ive use of clozapine in TRS?
• What is the methodological quality of the evidence that is
available exploring the barriers to optimal use of clozapine?
Method
We followed the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement guide-
lines.14 A protocol deﬁning the key methodological para-
meters was developed prior to the literature search and
was registered at the International Prospective Register of
Systematic Reviews (PROSPERO).15
Search strategy
Electronic databases (PsycINFO, Medline, PubMed, AMED,
CINHAL and EMBASE) from 1972 onwards were searched,
followed by a search of the reference lists of the full texts
of the retrieved articles for further relevant articles. The fol-
lowing search terms were used: treatment-resistant schizo-
phrenia, clozapine, barriers, use, prescription rates,
implementation, clozaril and prescribing practices. These
keywords were searched for in the title, keywords, or
abstract. Truncations and related terms were used as appro-
priate based on individual database procedures. The search
was last updated in March 2018.
All study types (intervention, observational and descrip-
tive) were included in the review if the following inclusion
criteria were met.
• Adult populations with a diagnosis of TRS for whatever
indication. Clozapine has been used for other diagnoses;
however, we limited our present review to TRS.
• Included primary research information on the outcome
variables, i.e. barriers or factors associated with low use
or implementation strategies.
• Published between 1972 and 2018.
Studies that examined the pattern of use of clozapine,
the rate of prescriptions, or its eﬃcacy and eﬀectiveness
were excluded, unless these provided data on the barriers
or factors associated with low or high use of clozapine.
There is no agreed deﬁnition of the ‘optimal use’ of clo-
zapine. However, a number of studies9–11,16 indicate that the
optimal use is determined on the basis of time since the
start of the ﬁrst antipsychotics (considering that clozapine
is used after failure to respond to two antipsychotics) and
the prevalence of clozapine prescription relative to total anti-
psychotic prescriptions (based on fact that about 30% of those
suﬀering from schizophrenia develop TRS). These provide
useful guidance but do not take into practical factors such
as patient willingness to start clozapine or non-availability,
or the cost of clozapine in low- and middle-income country
settings. We used these parameters as a broad guideline for
our review, but we will also report clozapine use and how it
is deﬁned as adequate or optimal by diﬀerent studies.
Data extraction
The screening for searches examining the relevant abstracts,
examination of full-text articles and data extraction were
done by two reviewers independently, as outlined in the
protocol.15 Any disagreements were resolved by consensus
and, where appropriate, by consultation with the third
reviewer. A data extraction sheet was developed based on
the pre-speciﬁed outcomes and relevant data were extracted
on to this sheet. We planned a meta-analysis of primary and
secondary outcomes, but it was not possible to statistically
summarise the data owing to the heterogeneity of studies,
lack of adequate data and low quality of studies. We instead
provide a descriptive summary of main ﬁndings.
Results
The electronic searches returned 253 relevant abstracts and
titles; no further articles were identiﬁed from the other
sources. We screened the titles and abstracts, and excluded
any studies that were not directly relevant to the objectives
of the review. After screening these titles and abstracts and
removal of duplicates, we further examined 47 full-text
papers. Finally, we included 15 papers in the review. The
details of the search yield and reasons for excluding full-text
articles are provided in Fig. 1.
Characteristics of included studies
The studies were conducted in a number of diﬀerent popu-
lations, settings and periods, and also used diverse method-
ologies. Owing to the diverse methodologies and number of
variables examined across studies, it was inappropriate to
pool the data to produce a statistical summary. We therefore
describe the main ﬁndings and produce a narrative summary
of results.
Fifteen studies met the inclusion criteria. Twelve of these
studies focused on barriers or factors associated with cloza-
pine use. These comprised surveys (n = 5), case note reviews
(n = 4), and semi/structured interviews and consultations
with stakeholders (n = 3). The majority of these studies (n =
8) involved eliciting views from clinicians, particularly con-
sultant psychiatrists. Three studies described interventions
or quality improvement initiatives to facilitate the use of clo-
zapine. These are described separately.
In survey-based studies, response rates varied from 8.8
to 76%. The mean response rate from the papers which
had ﬁgures available (n = 5) was 52.3%. The total number of
males from the studies providing this information (n = 6)
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was 608, and the number of females was 402. The popula-
tions in these studies comprised 902 psychiatrists, 68 trai-
nees, 49 pharmacy staﬀ and 15 nursing staﬀ or staﬀ in
mental health leadership positions. One database study
reviewed the Medicaid patients on antipsychotic medication
using records of 629 800 patients in the analysis.
In the three intervention studies, 158 participants were
involved. One study did not provide details of sample size.
The characteristics of included studies are shown in
Table 1.
Barriers to the use of clozapine in TRS
It was possible to classify the barriers in three groups with
some overlap:
• barriers related to patients and the drug;
• clinician-related barriers;
• health system-related factors.
Patient- and drug-related barriers
Five studies commented on patient-related factors aﬀecting
the use of clozapine in TRS. The complete refusal of
blood tests was considered a major barrier, with patients
delaying the initiating of clozapine (56%, n = 72).17 This
was replicated by Kelly et al,18 who surveyed psychiatrists
in Maryland, USA, and found that the main barrier, ranked
highest on the Likert scale (1–5), was patient non-adherence
with blood work (3.7 ± 1.1) and the burden of blood work on
the patient (3.6 ± 1.2).18 In a survey of patients, Swinton and
Ahmed (1999)19 reported that almost two-thirds of partici-
pants did not want the burden of regular blood tests. This
was replicated in a survey of staﬀ, with 65% (n = 83) report-
ing that patients did not want the burden of regular blood
tests and that frequent blood tests were considered a major
barrier to initiating clozapine.17
Concerns about tolerating clozapine were considered to
be fairly or very frequently related to delays in clozapine use
by 46% (n = 59) of clinical staﬀ.17 Complications related to
clozapine, such as constipation, hypersalivation, myocarditis
and neutropenia, can inhibit clozapine use; a survey of clinical
staﬀ found that 37% (n = 76) felt that these potential medical
complications frequently restricted the use of clozapine.17
Najim et al20 reviewed 42 case notes of patients on clo-
zapine and found that there were signiﬁcant delays in com-
mencing clozapine in patients aged over 30.20 This was
replicated by Grover et al,21 who carried out a case note
review on 200 in-patients from a tertiary care centre in
North India. A greater delay in initiating clozapine was
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Fig. 1 Summary of the abstracts reviewed to identify papers relevant for the review.
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noted in the older age group (over 20) compared with those
under 20 (mean 0.91 v. 2.05; s.d. 1.05 v. 1.86).21 In addition,
they found a signiﬁcant delay in patients prescribed poly-
pharmacy compared with non-polypharmacy (mean 2.58 v.
1.68; s.d. 2.06 v. 1.67), and delays were also associated with
being in an urban locality (mean 2.11 v. 1.37; s.d. 1.98 v. 1.11).21
Clinician-related factors
Inadequate knowledge of or experience in clozapine use.
Fifty-two per cent (n = 75) of staﬀ surveyed in South
London Maudsley NHS Foundation Trust17 reported not
being familiar with initiation of clozapine. In another large
survey, 74% (n = 136 total 184) of psychiatrists working in
Table 1 Characteristic of included studies
Author/year Population Method/design
Sample characteristics and
response rates (ReR)
1. Gees et al (2013) All staﬀ at South London and Maudsley NHS
Foundation Trust
Survey n = 144
Trainee doctors 42% n = 60
Consultants 14% n = 20
Pharmacy staﬀ 16% n = 23
2. Cirulli (2005)24 Consultant psychiatrists working in child and
adolescent mental health services in-patient
unit
Survey n = 83
ReR 59 (71%)
3. Najim et al (2013)20 Out-patients on clozapine in UK community
population
Retrospective case note review n = 42
ReR 100%
4. Swinton & Ahmed
(1999)19
In-patients in high-secure hospital – patients,
consultants, nurses
Case note review and survey of
patients and staﬀ
n = 95
ReR 72 (76%)
5. Grover et al
(2015)21
Patients initiated on clozapine in North India
tertiary hospital (Jan 2006–June 2014)
Retrospective record review n = 200 patients
6. Tungaraza & Farooq
(2015)22
Psychiatrists Survey n = 2771
ReR 243 (8.8%)
7. Apiquian et al
(2004)23
Psychiatrists Survey n = 200
ReR - 148 (74%)
8. Goren et al (2016)26 Key informants (Psychiatrists, clinical
pharmacists, advanced practice nurses)
involved in the clozapine process at US
Department of Veteran Aﬀairs with high and
low utilization of clozapine
Semi structured telephone interviews n = 70 participants
Psychiatrist 31.4%
Pharmacy staﬀ 37.1%
Mental health leadership
15.7%
Advanced practice nurse
5.7%
Other 10%
9. Kelly et al (2015)18 Psychiatry residents, fellows, and psychiatrists
in the state of Maryland
Survey with each question rated using
Likert scale: 1 = strongly disagree, 5 =
strongly agree
n = 860
ReR 277 (32%)
10. Stroup et al
(2014)25
Patients with schizophrenia spectrum disorder,
using Medicaid data from 2001 to 2005, who
used clozapine or standard antipsychotic
medication in one or more treatment episodes
Comparison between standard
antipsychotic and clozapine use, using
statistical analysis
n = Patients on clozapine
(n = 15 524)
Patients on other
antipsychotics (n = 614
285)
11. Nielson et al
(2009)13
Psychiatrists from six counties in Denmark;
three highest and three lowest prescription
rates of clozapine
Structured interview n = 100
72 Consultant psychiatrists
20 psychiatrists
8 trainee psychiatrists
12. Kelly et al (2018)27 Clinicians and researchers identiﬁed by the
National Association of State Mental Health
Program Directors
Expert opinion, literature review and
focus group
11 Psychiatrists and
researchers; however, no
speciﬁc details given
Intervention studies
13. Carruthers et al
(2016)28
Academics and clinicians in clozapine
prescribing and patients with
treatment-resistant schizophrenia in receipt of
Medicaid in New York
Educational initiative utilizing
web-based modules to educate
consumers and carers as well as
clinicians regarding clozapine use
No sample details provided
14. Nielson et al
(2012)13
Psychiatric out-patients on treatment with
clozapine in Denmark
Point-of-care (POC) testing using
capillary sampling v. venous sampling
85 participants
15. Bogers et al
(2015)29
Patients established on clozapine Randomised cross-over trial design for
POC testing using capillary sampling v.
venous sampling
73 patients were included in
this study; three dropped
out before completion
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the UK also highlighted a lack of knowledge or experience
amongst consultants, leading to delays.22 A signiﬁcant num-
ber of consultants (42%; n = 96) had fewer than ﬁve patients
on clozapine, despite half of these consultants working in
trusts with a dedicated clozapine service and having
been in-post for 7 years.22 This was replicated by Nielson
et al (2009), who found that 48% of psychiatrists surveyed
had treatment responsibility for fewer than ﬁve patients trea-
ted with clozapine.13 In Mexico, Apiquian et al23 reported that
fewer than half of the 200 surveyed psychiatrists in Mexico
knew the recommended average dose of clozapine.23
The fear of side-eﬀects or lack of knowledge in dealing
with these were considered to be serious hurdles in initiat-
ing clozapine. Sixty per cent (n = 70) of practitioners sur-
veyed in South London and Maudsley NHS Foundation
Trust raised concerns about tolerability and side-eﬀects
that delayed the initiation of clozapine.17 Nielson et al13
reported that in terms of side-eﬀects and knowledge, only
33% (n = 33) knew that the risk of agranulocytosis was high-
est in the ﬁrst 6 months and 23% (n = 23) overestimated this
risk of agranulocytosis.13
The majority of the clinicians in a survey (78%; n = 105)
said they would support clozapine initiation after a trial of
two antipsychotics.17 However, Nielson et al (2009) found
that only 44.9% (n = 44) would go to clozapine after two anti-
psychotics,13 and about a third 30.6% (n = 30)13 of clinicians
in one survey and 14% (n = 19) in another would wait until
three adequate trials of antipsychotics prior to initiating clo-
zapine, while 18.4% (n = 19)13 would wait until more than
three failed adequate trials of antipsychotics. In another sur-
vey, 28% (n = 51, total 184) of consultants said they would
trial at least another antipsychotic before going to clozapine
after a failed trial of two antipsychotics,22 and 40.5% (n = 92)
preferred to use several other antipsychotics before cloza-
pine.19 Nielson et al13 found that 64.7% of psychiatrists sur-
veyed (n = 64) would rather combine two antipsychotics than
prescribe clozapine, and 15.2% (n = 15) would augment with
a mood stabiliser before using clozapine in a non-
schizoaﬀective state.13
Diﬃculty in identifying suitable patients and unclear
diagnosis were highlighted by 12% of consultant psychia-
trists (n = 22) in a survey conducted by Tungaraza &
Farooq.22 Although consultants felt they had good exposure
to clozapine as trainees, 36.2% (n = 83) felt it was not easy to
identify suitable patients for clozapine.22
Need for intense monitoring. Forty-two per cent (n = 77) of
psychiatrists in a UK-wide survey felt it was complex and
cumbersome to initiate and mange clozapine, which led to
delays in starting the drug.22 In a survey of consultants
based in child and adolescent psychiatry, 29% (n = 17)
reported that they did not prescribe clozapine owing to the
need for intense monitoring.24 Tungaraza & Farooq22
found that 74% (n = 136) of clinicians felt there were delays
owing to refusal of patients to have blood tests.22
Serious side-eﬀects. In a survey of consultant psychiatrists,
105 out of 231 respondents (45.5%) acknowledged that their
patients experienced untoward side-eﬀects while on cloza-
pine, which was considered to be major factor in delaying
clozapine use.22
Staﬀ in child and adolescent services highlighted
unfamiliarity with clozapine (41%; n = 4) and side-eﬀects
(41%; n = 4)24 as major factors in delaying clozapine initi-
ation. Swinton & Ahmed19 reported that 22% (n = 7) of the
clinical staﬀ in their study believed that the risks associated
with clozapine outweighed the beneﬁts of starting clozapine.19
Perception that patients may not adhere to treatment. Clinical
staﬀ surveyed at a high-secure hospital reported likely poor
adherence by the patients as a reason for not prescribing clo-
zapine in 53% of cases (n = 17).19 Other clinical staﬀ reported
that patients were likely to refuse blood tests 43% (n = 13).19
Tungaraza & Farooq22 reported that 54% (n = 99) of prac-
ticing psychiatrists felt that likely poor adherence to the
drug was a reason for delays.22
Health system-related barriers
Studies based on clinician surveys identiﬁed the following
health system-related barriers.
(a) Diﬃculties in obtaining baseline bloods and the time
taken to register patients for blood monitoring were
considered as major factors in initiating clozapine
by 22% (n = 26) clinicians.17
(b) Staﬀ resources, including inadequate staﬀ to monitor
clozapine initiation, were a major factor for 22% (n =
26) of clinicians in delaying clozapine initiation.17
(c) The need for admission as required by some health
providers to initiate clozapine and a shortage of
beds were highlighted by 20% (n = 23) of clinical
staﬀ.17 In another survey, 32% (n = 40) of clinical
staﬀ felt that a lack of resources in the home treat-
ment team led to frequent delays in commencing
clozapine.17
(d) Service fragmentation owing to separate teams pro-
viding community and in-patient services and a lack
of community support were cited as major barriers
(n = 39) by clinicians in one study.22 A survey of
staﬀ at Ashworth high-secure hospital also revealed
that clinicians felt that a lack of resources was
responsible for delays or non-prescription of cloza-
pine in 16% (n = 5) of cases.19
Stroup et al25 conducted a retrospective study using
Medicaid claims data from 45 states in the USA. It was
found that among 629 809 unique antipsychotic treatment
episodes, 79 934 showed service use patterns consistent
with treatment resistance. Clozapine accounted for 2.5%
of starts of antipsychotic medication among patients in
the overall sample, and 5.5% of starts among patients with
treatment resistance. Clozapine initiation was signiﬁcantly
associated with male sex, younger age, White ethnicity,
more frequent out-patient service use for schizophrenia,
and greater prior-year hospital use for mental health.25
Patients residing in counties with historically high clozapine
usage were almost twice as likely to start clozapine as
patients residing in historically low-use counties (adjusted
odds ratio (AOR) 2.03; CI 1.75–2.30).25 A high concentration
of psychiatrists (>15 per 100 000 residents) was also asso-
ciated with a greater likelihood of clozapine initiation
(AOR 1.17; CI 1.03–1.33).25 However, there were no
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signiﬁcant eﬀects of population density or measures of pov-
erty or income on clozapine initiation.
Goren et al26 carried out 70 semi-structured interviews
with stakeholders such as psychiatrists, mental health
nurses, and pharmacy and laboratory staﬀ at ﬁve sites with
high clozapine use and ﬁve low-utilization sites. Low utiliza-
tion of clozapine was associated with a lack of champions to
support the clozapine process. Some of the barriers high-
lighted included the complex and time-consuming paper-
work.26 Lack of transport, particularly for rural patients,
inability by disorganised patients to navigate public trans-
port, paranoia around travelling by public transport and
the cost of transportation26 were reported as major barriers.
Patients living far away from clinics were not considered
suitable for clozapine owing to their inability to attend for
regular blood tests.26
Kelly et al18 elicited the views of psychiatrists using an
anonymous survey questionnaire. The questionnaire con-
sisted of 56 questions to be scored on a ﬁve-point Likert
scale (1 = strongly disagree, 5 = strongly agree) regarding
the barriers related to clozapine, and the physician’s interest
and willingness to use point-of-care (POC) devices. The sur-
vey was sent to 860 psychiatrists, of whom 277 (32%)
responded. Among the 28 listed barriers (clinical, non-
clinical, and side-eﬀects) to more frequent use of clozapine,
the two highest ranking barriers were: (a) the likely non-
adherence of patients to blood work (score 3.7 ± 1.1) and
(b) the burden of ongoing blood monitoring for the patient
(score 3.6 ± 1.2). Among nine potential solutions for increas-
ing the use of clozapine, the use of POC devices was the
highest ranked. The physicians agreed that a POC device
would improve care and that it would increase their cloza-
pine use with a mean score of 3.9 ± 1.0.18
The National Association of State Mental Health
Program Directors (NASMHPD) in in the USA formed a
working group to identify barriers to clozapine underutiliza-
tion and interventions to overcome these at a national
level.27 The initial work group included 11 clinicians and
researchers and consulted a wide range of stakeholders and
existing literature on the subject. They identiﬁed 14 major
barriers, which included all the factors mentioned above,
as well as benign ethnic neutropenia (BEN), which occurs
among people of African or Middle Eastern ancestry. The
lack of a deﬁnition for BEN in product labelling and clear
guidance on monitoring requirements may be responsible
for the low use of clozapine in this population. A lack of
standardised materials for shared decision-making, complex
protocols for treatment monitoring and management of
side-eﬀects, formulary issues and costs of ancillary services
such as transportation and service coordination were also
identiﬁed as barriers (Box 1).27
Interventions to overcome the barriers
Three studies described interventions that could help to
overcome the barriers identiﬁed above. These included a
training initiative28 and two studies describing the use of
POC devices.28,29 As these studies employed diﬀerent meth-
odologies and interventions, the results are brieﬂy sum-
marised here.
Bogers et al29 compared a POC device using capillary
blood sampling with a ﬁnger prick that provided WBC
counts with conventional venous sampling. An open-label
randomised cross-over trial design was used to compare
the two procedures. The main outcome measure was the
subjective experience of various aspects of blood sampling,
as measured by a visual analogue scale (VAS). A consistent
pattern in favour of capillary blood sampling was found
(total perceived burden blood sampling: capillary 5.79 v. ven-
ous 13.4 (P < 0.001)). Both patients and practitioners showed
preferences for the capillary blood sampling.29
Similarly, Nielsen et al30 evaluated a POC using a rando-
mised cross-over trial design. Patients were randomised to
one of two blood monitoring sequences. The ﬁrst group
underwent venous sampling followed by capillary sampling
in a twice-repeated procedure (venous–capillary–venous–
capillary); in the other, the sequence was reversed (capil-
lary–venous–capillary–venous). Eighty-ﬁve patients were
Box 1. Barriers to clozapine use and strategies to overcome these
Barriers to clozapine use
Patient/drug-related barriers
• Refusal of blood tests17–19
• Tolerating clozapine and side-effects17
• Age > 2019,20
• Patients prescribed polypharmacy21
• Benign ethnic neutropenia27
Clinician-related barriers
• Inadequate knowledge of or experience in clozapine use17,22–24
• Fear of side-effects for patient/lack of knowledge about clo-
zapine side-effects13,17,19,22,24
• Lack of adherence to guidance13,17,22
• Difficulty identifying suitable patients and unclear diagnoses22
• Need for intense monitoring22,24
• Perception that patients may not comply with treatment19,22
Health system-related barriers
• Not enough resources, including not enough staff resources to
monitor clozapine inititation17
• Shortage of beds17
• Service fragmentation21
• Lack of champions to support the clozapine process26
• Complex and time-consuming paperwork26
• Lack of standardised shared decision-making27
• Complex protocols for treatment monitoring27
• Formulary issues and costs of ancillary services such as
transport and service coordination27
Strategies to overcome barriers to clozapine use
• Use of POC devices29
• Support for prescribers and decision-aid tool for consumers
grounded in principles of shared decision-making27
• Internet-based educational programmes to provide information
for consumers, family members and clincians27
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included in the study using a VAS; patients indicated that
they found capillary blood monitoring less painful than ven-
ous sampling (VAS ratings: 0.55 cm 25–75th percentiles: 0.1–
1.4 cm v.. 1.75 cm 25–75th percentiles: 0.7–2.6, P < 0.001).
They also felt less inconvenienced by the POC method
than by traditional blood sampling.30
Carruthers et al28 described an educational intervention
to promote the evidence-based use of clozapine in New
York,28 consisting of support for the prescriber and a decision
aid tool for consumers grounded in the principle of shared
decision-making. A manual for clinicians was developed and
academics presented a series of state-wide grand rounds pre-
sentations to provide information on clozapine prescribing.
Internet-based educational programmes and a telephone con-
sultation service by experts to support the prescribers were
also provided. A key component of the programme was testi-
monials from patients, who described personal beneﬁts along-
side the challenges.28 The programme was evaluated using
Medicaid data on the pattern of new antipsychotic start-ups.
The number of new starts amongst all antipsychotic trials
increased from 1.5% in 2009 to 2.1% 2013.28 The greatest
change was seen in state-operated facilities, where the rate
of clozapine new starts per quarter increased compared with
all new antipsychotic starts. The change in the rate of cloza-
pine new starts in these facilities was three times higher
than in other settings (3.77% v. 1.13%).28
Quality assessment of included studies
The published protocol outlined separate quality assess-
ments for qualitative and quantitative studies, using appro-
priate checklists for diﬀerent study designs.15 However,
after examining the included studies, it was felt that only
two trials29,30 could be assessed for quality using the risk
of bias tool, as per protocol. These randomised cross-over
trials compared capillary blood sampling using a POC device
with traditional venous blood sampling. Patients were ran-
domised to two sequences, starting with either capillary or
venous blood sampling, followed by a repeated sequence.
Neither of these trials provided details of how participants
were randomly allocated to the two sequences, and the out-
come assessments did not appear to have been done by blind
assessors. Both studies had high risk of bias.
Other studies did not use appropriate study designs,
which could be evaluated using the checklists we proposed
in the protocol for observational studies. These studies
were mostly surveys and provided little information on
how the samples were selected and the validity or reliability
of the questionnaires/instruments used, or any information
on non-responders. All these studies were considered to be
of low quality.
Discussion
This was the ﬁrst systematic review aiming to examine the
barriers to eﬀective use of clozapine. The following major
barriers or factors related were identiﬁed: the mandatory
blood testing requirement; fear of serious side-eﬀects, lack
of familiarity in use of clozapine; lack of clarity in diagnosis
and diﬃculty in identifying suitable patients; service frag-
mentation; and lack of adequate training in or exposure to
using clozapine. Only one educational intervention was
available that showed some eﬀect on clozapine prescription
rate. POC testing using capillary blood was more acceptable
to patients than traditional blood sampling, being less pain-
ful and less time consuming, but no studies tested whether it
increased the uptake of clozapine.
A conservative estimate suggests that TRS adds more
than $34 billion in annual direct medical costs in the
USA.31 In the UK, NICE has included the extent and the
degree of clozapine use in the quality criteria for commis-
sioners when commissioning services for mental health.32
However, initiatives to overcome this major service need
are rare.
Almost all studies highlighted routine blood monitoring
as the top-ranking barrier to initiating and maintaining clo-
zapine treatment. Two randomised cross-over trials showed
that blood testing using a simple ﬁnger prick that was under-
taken as part of routine assessment by psychiatric staﬀ,
either in the patient’s home or at a psychiatric out-patient
clinic, was feasible and convenient for patients. However,
none of these trials looked at the eﬀect of POC testing on
prescription rates. The POC devices will also need to comply
with regulatory requirements for monitoring blood counts.
It appears that there is a common perception amongst
clinicians that clozapine is a dangerous drug, and that
patients will not adhere to it or would not like to consider
it as a treatment option. The ﬁndings in this review suggest
that these negative beliefs about clozapine result from a lack
of experience and knowledge, owing to the current limited
use of clozapine. A self-perpetuating cycle can ensue, as
practitioners do not see the beneﬁts of clozapine, and thus
do not develop conﬁdence in its use.1 This is consistent
with the study by Stroup et al which showed that higher clo-
zapine initiation was signiﬁcantly associated with patients
residing in areas associated with historically high clozapine
usage and higher concentrations of psychiatrists (>15 per
100 000 population).25
The NASMHPD published 36 recommendations on its
website for expanding the use of clozapine.33 One important
recommendation included improving residency trainee stan-
dards. Considering the disease burden resulting from TRS
and the central role of clozapine in its treatment, we suggest
that training in the use of clozapine becomes a mandatory
requirement for all psychiatry residence and continuing pro-
fessional development programmes. A certiﬁcation requiring
competence in initiating, maintaining and managing side-
eﬀects of clozapine is required, based on clinical experience,
similar to the certiﬁcation that is now required for electro-
convulsive therapy.
The use of clozapine is alarmingly low in many develop-
ing countries. In Pakistan, for example, about 1300 patients
were receiving clozapine as recorded in the Clozaril Patient
Monitoring System. Although generic clozapine has become
available recently, numbers are still very low, considering
that the country has a population of about 200 million
(R. U. Rahman, personal communication, 2016; data avail-
able from the authors on request). To put this prescription
rate into perspective, The Netherlands, with a population
of about 17 million, has over 12000 patients on clozapine,
which is 0.07% of the population (https://www.gipdata
bank.nl/). This means that, at current rates of use, there is
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a more than 100-fold diﬀerence between the two countries.
This situation requires a public health intervention to
improve access to clozapine in certain countries.
The major limitation of the review was the low quality
of the included studies. Studies were based on surveys,
which are prone to a number of biases, including selection
bias of respondents, and lacked control groups. The low
numbers of studies from a few countries also limit the gen-
eralisation of results. None of the studies deﬁned the opti-
mal use of clozapine. The lack of patient perspectives is
striking, considering that a number of studies suggested
patient-related factors as major barriers.
Despite these limitations, this systematic review indi-
cates that there is broad agreement on the major barriers
that hinder the eﬀective use of clozapine. There is certainly
a need to improve the methodological quality of studies and
the way these are reported, but the present study identiﬁes
gaps in clinical practice and health services that can be
addressed in intervention studies. Use of POC devices,
educational interventions targeting clinicians and shared
decision-making involving patients need to be evaluated
using controlled study designs. Future research should be
guided by the implementation science methods and behaviour
change principles that have successfully been used in
implementing and evaluating evidence-based interventions
in medicine.
About the authors
Saeed Farooq is a clinical senior lecturer at the Research
Institute for Primary Care & Health Sciences, Keele
University, a visiting professor at the University of Chester
and Honorary Consultant Psychiatrist, Midlands Partnership
NHS Foundation Trust, UK. Abid Choudry is an ST6 at
Forward Thinking Birmingham, Birmingham Women’s and
Children’s NHS Foundation Trust, UK.Dan Cohen is a psychi-
atrist at the Department of Community Mental Health, Mental
Health Organization North‐Holland NorthHeerhugowaard,
The Netherlands. Farooq Naeem is a professor at the
University of Toronto and a staﬀ psychiatrist at the Centre
for Addiction and Mental Health, Toronto, Canada.
Muhammad Ayub is a professor and Chair of the Division of
Developmental Disabilities at the Department of Psychiatry,
Queen’s University, Kingston, Canada.
References
1 Farooq S, Taylor M. Clozapine. Br J Psychiatry 2011; 198(4): 247–9.
2 Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM.
Second-generation versus ﬁrst-generation antipsychotic drugs for
schizophrenia: a metaanalysis. Lancet 2009; 373: 31–41.
3 McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY,
Rosenheck RA, et al. Eﬀectiveness of clozapine versus olanzapine, que-
tiapine, and risperidone in patients with chronic schizophrenia who did
not respond to prior atypical antipsychotic treatment. Am J Psychiatry
2006; 163: 600–10.
4 Lewis SW, Barnes TRE, Davies L, Murray RM, Dunn G, Hayhurst KP,
et al. Randomized controlled trial of eﬀect of prescription of clozapine
versus other second-generation antipsychotic drugs in resistant schizo-
phrenia. Schizophr Bull 2006; 32: 715–23.
5 Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB. Atypical
antipsychotic agents in the treatment of violent patients with schizophre-
nia and schizoaﬀective disorder. Arch Gen Psychiatry 2006; 63: 622–9.
6 Brunette MF, Drake RE, Xie H, McHugo GJ, Green AI. Clozapine use
and relapses of substance use disorder among patients with co-occur-
ring schizophrenia and substance use disorders. Schizophr Bull 2006;
32: 637.
7 Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen
A, et al. 11-year follow-up of mortality in patients with schizophrenia:
a population-based cohort study (FIN11 study). Lancet 2009; 374:
620–7.
8 Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice
guidelines and prescribing trends. BMC Psychiatry 2014; 14: 102.
9 Downs J, Zinkler M. Clozapine: national review of postcode prescribing.
Psychiatr Bull 2007; 31: 384–7.
10 Howes O, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D.
Adherence to treatment guidelines in clinical practice: study of anti-
psychotic treatment prior to clozapine initiation. Br J Psychiatry 2012;
201(6): 481–5.
11 Wheeler AJ. Treatment pathway and patterns of clozapine prescribing
for schizophrenia in New Zealand. Ann Pharmacother 2008; 42(6):
852–60.
12 Torrey EF, Knable MB, Quanbeck C, et al. Clozapine for Treating
Schizophrenia: A Comparison of the States. Treatment Advocacy Center,
2015 (http://www.treatmentadvocacycenter.org/storage/documents/
clozapine-for-treating-schizophrenia.pdf).
13 Nielsen J, Dahm M, Lublin H, Taylor D. Psychiatrists’ attitude towards
and knowledge of clozapine treatment. J Psychopharmacol 2009;
24(7): 965–71.
14 Moher D, Liberati A, Tetzlaﬀ J, Altman DG. Preferred reporting items
for systematic reviews and meta-analyses: the PRISMA statement.
Ann Intern Med 2009; 151(4): 264–9.
15 Farooq S, Choudry A, Cohen D, Naeem F, Ayub M. Barriers to optimum
use of clozapine in Treatment Resistant Schziophrenia (TRS): a systematic
review. PROSPERO 2017; CRD42017059434 (available from http://www.
crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42017059434).
16 Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in
patients currently receiving clozapine: a case note review. J Clin
Psychiatry 2003; 64: 30–4.
17 Gee S, Vergunst F, Howes O, Taylor D. Practitioner attitudes to cloza-
pine initiation. Acta Psychiatr Scand 2014; 130(1): 16–24.
18 Kelly DL, Ben-Yoav H, Payne GF, Winkler TE, Chocron SE, Kim E, et al.
Blood draw barriers for treatment with clozapine and development of
point-of-care monitoring device. Clin Schizophr Relat Psychoses Spring
2018; 12(1): 23–30.
19 Swinton M, Ahmed AG. Reasons for non‐prescription of clozapine in
treatment‐resistant schizophrenia. Crim Behav Ment Health 1999; 9(3):
207–14.
20 Najim H, Heath D, Singh P. Antipsychotic prescribing before clozapine
in a community psychiatric hospital: a case note review. Psychiatr
Danub 2013; 25(Suppl 2): S165–70.
21 Grover S, Hazari N, Chakrabarti S, Avasthi A. Delay in initiation of clo-
zapine: a retrospective study from a tertiary care hospital in North India.
Psychiatry Res 2015; 226(1): 181–5.
22 Tungaraza TE, Farooq S. Clozapine prescribing in the UK: views and
experience of consultant psychiatrists. Ther Adv Psychopharmacol
2015; 5(2): 88–96.
23 Apiquian R, Fresán A, De la Fuente-Sandoval C, Ulloa RE, Nicolini H.
Survey on schizophrenia treatment in Mexico: perception and anti-
psychotic prescription patterns. BMC Psychiatry 2004; 4(1): 12.
24 Cirulli G. Clozapine prescribing in adolescent psychiatry: survey of
prescribing practice in in-patient units. The Psychiatrist 2005; 29(10):
377–80.
25 Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M. Geographic and
clinical variation in clozapine use in the United States. Psychiatr Serv
2014; 65(2): 186–92.
8
ORIGINAL PAPER
Farooq et al Barriers to using clozapine in treatment-resistant schizophrenia
26 Gören JL, Rose AJ, Engle RL, Smith EG, Christopher ML, Rickles NM,
et al. Organizational characteristics of Veterans Aﬀairs clinics with
high and low utilization of clozapine. Psychiatr Serv 2016; 67(11):
1189–96.
27 Kelly DL, et al. Addressing barriers to clozapine underutilization: a
national eﬀort. Psychiatr Serv 2018; 69: 224–7.
28 Carruthers J, Radigan M, Erlich MD, Gu G, Wang R, Frimpong EY, et al.
An initiative to improve clozapine prescribing in New York State.
Psychiatr Serv 2015; 67(4): 369–71.
29 Bogers JP, Bui H, Herruer M, Cohen D. Capillary compared to
venous blood sampling in clozapine treatment: patients׳ and health-
care practitioners׳ experiences with a point-of-care device. Eur
Neuropsychopharmacol 2015; 25(3): 319–24.
30 Nielsen J, Thode D, Stenager E, Andersen KØ, Sondrup U, Hansen TN,
et al. Hematological clozapine monitoring with a point-of-care device: a
randomized cross-over trial. Eur Neuropsychopharmacol 2012; 22(6):
401–5.
31 Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC. The social
and economic burden of treatment-resistant schizophrenia: a system-
atic literature review. Int Clin Psychopharmacol 2014; 29(2): 63–76.
32 NICE Guidance Quality Standard 80. Psychosis and Schizophrenia in
Adults. 2015. (https://www.nice.org.uk/guidance/qs80).
33 Love RC, Kelly DL, Freudenreich O, et al. Clozapine Underutilization:
Addressing the Barriers. National Association of State Mental Health
Program Directors, 2016 (http://nasmhpd.org/sites/default/ﬁles/
Assessment%201_Clozapine%20Underutilization.pdf).
9
ORIGINAL PAPER
Farooq et al Barriers to using clozapine in treatment-resistant schizophrenia
